{'fraction_non_alphanumeric': 0.023668639053254437, 'fraction_numerical': 0.014792899408284023, 'mean_word_length': 5.904761904761905, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Urinary lysozyme levels in primary nephrotic syndrome and amyloidosis

Urinary lysozyme activity mainly reflects tubular injury. Urinary and serum lysozyme levels along with other routine measures were assessed in normal controls, eight idiopathic nephrotic syndrome and 13 renal amyloidosis patients. Using urinary lysozyme (Lzm), serum Lzm and urine Lzm/urine creatinine values as independent variables a Y value was defined to discriminate between amyloidosis, idiopathic nephrotic syndrome and normals. When four additional variables were included (serum protein, albumin, urine protein/urine creatinin and urine Lzm/urine protein ratios) another Y value was defined to discriminate between amyloidosis and idiopathic nephrotic syndrome cases. Thus these measurements may be used in selected cases to identify idiopathic nephrotic syndrome patients before performing a renal biopsy and save the amyloidosis patients from the deleterious effects of corticosteroid treatment. [Turk J Med Res 1993;11(5): 237-239]